Human proinsulin: bioactivity and pharmaco-kinetics after intravenous and subcutaneous administration.
The hypoglycemic actions of biosynthetic human proinsulin and human insulin (1 IU insulin/kg b.w. and about equimolar amounts of proinsulin) were studied after intravenous and subcutaneous injection in rabbits. Blood samples were taken up to four hours after injection for the determination of blood glucose and immunoreactive levels of both insulin and human C-peptide. For the determination of human C-peptide, serum taken after proinsulin injection was divided into two fractions. One was examined directly by the human C-peptide radioimmunoassay and the other after incubation with a protein-A-sepharose coupled insulin antibody to find "free human C-peptide". In amounts equimolar to 1 IU insulin/kg b.w., proinsulin exerted an about one third stronger hypoglycemic action (area under curve estimation) after s.c. compared to i.v. injection. Proinsulin-induced hypoglycemia did not last longer after intravenous administration than that induced by intravenous insulin. Although subcutaneous proinsulin did not show the same maximum decrease of blood glucose as subcutaneous insulin, its action was significantly prolonged (up to 180 min). Specific measurement of free human C-peptide showed no evidence of conversion of proinsulin to insulin and C-peptide.